Cross-Sector entity
Of the tracked stories, 4 of 6 also mention Ark Investment Management, the most common co-covered peer. The 163-day window averages about 0.3 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 2 of those 6, with the remainder spread across 4 other categories.
6 verified stories tracked
Last mentioned: Aug 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 6 also mention Ark Investment Management, the most common co-covered peer. The 163-day window averages about 0.3 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 2 of those 6, with the remainder spread across 4 other categories. The tracked stories average 2.5 original sources each. 0% of these stories carry negative sentiment. This profile follows 6 Cross-Sector stories mentioning Tempus AI, Inc. across the period from March 16, 2026 to August 25, 2026.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tempus AI, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Tempus AI announced FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled tool that analyzes standard 12-lead ECGs for pulmonary hypertension signs. The device targets symptomatic adults 40 and older, aiming to address underdiagnosis without invasive procedures.
Tempus's ECG-PH AI model analyzes raw 12-lead ECG waveforms for binary signs associated with elevated mPAP >20 mmHg, receiving FDA 510(k) clearance and marking the company's third cardiovascular AI device. This matters for ML teams as regulatory acceptance of diagnostic AI broadens.
Source: Times Argus · Financialcontent
Kadensa Capital Ltd reduced its position in Tempus AI (TEM) by 4.8% during the third quarter, signaling a tactical adjustment by the institutional investor. This move comes as the precision medicine firm sees high volatility and divergent sentiment among major funds, including aggressive buying from ARK Invest.
Source: Daily Political · Ticker Report
ARK Invest CEO Cathie Wood has increased her position in Tempus AI with a $2 million purchase, signaling continued conviction in AI-driven healthcare despite a 15% year-to-date decline. This move comes as Wood's flagship ARKK fund faces renewed pressure, trailing the S&P 500 significantly over a five-year horizon.
ARK Invest CEO Cathie Wood has increased her stake in Tempus AI with a $2 million purchase, signaling continued conviction in high-growth technology despite a 15% year-to-date decline for the stock. This move comes as her flagship Ark Innovation ETF struggles to keep pace with the broader market, currently trailing the S&P 500 as Wood maintains her stance that the AI sector is far from a bubble.
Cathie Wood's ARK Investment Management has purchased $2 million worth of Tempus AI shares, reinforcing its position in the precision medicine firm despite a 15% year-to-date decline. The move underscores Wood's commitment to 'coiled spring' AI and biotech assets, even as her flagship funds face significant performance headwinds compared to the broader market.
Source: Kansascity · Miamiherald
